Added to YB: 2025-09-19
Pitch date: 2025-09-18
NVO [bullish]
Novo Nordisk A/S
-22.08%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 394.50
Price Target
70.00 (-77%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
Actionable Stock Set-up 8: Novo Nordisk (NVO)
NVO: Down 60% from highs but dominant in vast diabetes (589M→850M patients by 2050) & obesity (1.7B overweight) markets. 52% GLP-1 share, 57% obesity share. CagriSema pipeline drug shows 11.8% weight loss vs 2.3% placebo. New CEO restructuring, cutting 9K roles for DKK8B savings. Trades at historically low 14x PE despite 18% revenue growth.
Read full article (10 min)